Vuélvete ilimitado con Magzter GOLD

Vuélvete ilimitado con Magzter GOLD

Obtenga acceso ilimitado a más de 9000 revistas, periódicos e historias Premium por solo

$149.99
 
$74.99/Año

Intentar ORO - Gratis

Roche- Connecting dots for diabetes relief

BioSpectrum Asia

|

December 2019

At the International Diabetes Federation (IDF) Congress 2019 held from December 2 – 6, 2019 in Busan, Korea, Swiss multinational healthcare company Roche showcased few innovative digital solutions to address and manage the growing burden of diabetes globally. Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years.

Roche- Connecting dots for diabetes relief

A recent application by Roche Diabetes Care, on display at the IDF 2019 exhibition, was ACCU-CHEK SugarView. It is currently undergoing a pre-launch preview in India. Another product on display was the Accu Chek Solo micropump system that allows for convenience and personalisation in insulin pump therapy while contributing to a more targeted and effective diabetes management. The product was officially launched in 2018 and is currently available in many countries but yet to be launched in India and China, that are most affected by diabetes.

The RocheDiabetes Care platform was also exhibited at the event. This platform offers a lot of convenience to the healthcare providers on handling patient care with less time sorting through endless data. It was launched in March 2019 and is yet to reach the Indian market. Currently, the platform in available in Philippines, Spain, Portugal, France and Brazil. Adding to the list was Eversense Continuous Glucose Monitoring System also on display that offers a long-term continuous glucose monitor for diabetes management.

MÁS HISTORIAS DE BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Seeing Opportunity in Ophthalmology

Asia-Pacific is emerging as one of the most active regions for ophthalmology innovation. In recent months, a wave of cross-border partnerships and licensing deals has underscored both the scale of unmet need in eye disease and the region's growing ambition to play a larger role in treatment development. From glaucoma and retinal disorders to dry eye disease and childhood myopia, companies across pharma, biotech, and medtech are increasingly accelerating clinical progress.

time to read

6 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Reshaping Asia's Healthcare with mRNA Innovation

The COVID-19 pandemic acted as both a challenge and a catalyst, serving as a testbed that fundamentally reshaped the biotechnology landscape across Asia and beyond. What emerged during this period was not just a breakthrough moment for mRNA, but the early foundation of a broader transformation that is still unfolding.

time to read

2 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Momentum in Motion: What Will Shape APAC's Life Sciences Landscape in 2026?

Asia-Pacific's life sciences sector is growing rapidly, driven by its scale, diversity and resilience. Accelerating demographic change and strong investment in innovation position the region to outpace global growth and shape the future of healthcare.

time to read

5 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

The Future of mRNA Is Being Built in APAC

Beyond scientific advancement, mRNA represents a strategic opportunity shaped by policy stability, public investment and regional collaboration. Across APAC, governments are increasingly recognising that supportive regulatory frameworks and long-term funding can serve as powerful competitive advantages, attracting global capital and talent. While political dynamics in the United States have slowed momentum, experts emphasise that the science underpinning mRNA technology remains sound. To fully realise its potential, the region will need greater coordination across borders, including regulatory harmonisation and joint development pathways, to build a resilient mRNA ecosystem capable of addressing shared health challenges and driving long-term innovation.

time to read

25 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

How Precision Medicine Is Reshaping Cancer Care

Despite major advances in cancer detection and treatment, high recurrence rates and progression to advanced disease continue to challenge outcomes across Asia-making precision medicine a critical catalyst for shifting cancer care from disease management toward treat-to-cure. By leveraging molecular insights, biomarker testing and collaborative healthcare ecosystems, precision medicine offers the potential to deliver more effective, personalised and sustainable cancer care for patients across the region.

time to read

2 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

Repligen introduces next-generation chromatography resins

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, has announced the launch of three new high-performance chromatography resins:

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

Hanahealth by DSS Imagetech launches GERI Time-Lapse Incubator in India

Hanahealth by DSS Imagetech, the authorised partner of Sydney-based Genea Biomedx, has launched the advanced GERI Time-Lapse Incubator pan India. GERI, the nextgeneration Time Lapse embryo culture system from Genea Biomedx, is ideal for IVF clinics, labs adopting digital transformation, centres working toward accreditation, and research-focused fertility groups as it enables them to modernise their processes and improve IVF outcomes.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

Biotechnology to Drive Next Industrial Revolution: Dr Jitendra Singh

\"Biotechnology will play a defining role in shaping the next industrial revolution and will be a key driver of global and Indian economic growth\", said Dr Jitendra Singh, the Union Minister of State (Independent Charge) for Science and Technology.

time to read

1 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Cartherics names Dr lan Nisbet as CEO

Australia-based Cartherics, a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women's diseases, with lead programmes in ovarian cancer and endometriosis, has announced the appointment of Dr Ian Nisbet as Chief Executive Officer, as part of a planned leadership transition.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Neurophet ropes in Josh Cohen as Head of Americas Business

South Korea-based Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, has appointed Josh Cohen, a veteran executive from leading global medical device companies, as new Head of Americas Business.

time to read

1 min

BioSpectrum Asia Jan 2026

Translate

Share

-
+

Change font size